Peptides for energy and fatigue — what research has explored at the cellular and systemic level

The medical system is not particularly good at fatigue without a named cause. If there's anemia or thyroid disease or sleep apnea, those are findable and treatable. But the more common presentation — fatigue that is real and persistent, that does not respond to rest, that seems to reflect a general downregulation of capacity — often produces normal labs and a frustrating consultation. "Everyone is tired." The research literature on fatigue has expanded substantially in recent years, partly driven by post-viral fatigue syndromes, and it is increasingly clear that fatigue is not a single problem. It is a downstream symptom with many possible upstream generators, and matching the right intervention to the right mechanism requires identifying which generator is dominant.

Peptide research has become interested in fatigue from several directions simultaneously, and the landscape is best understood by following those distinct mechanistic threads rather than treating "peptides for energy" as a single category.

The most fundamental level is cellular. Every cell in your body runs on ATP — adenosine triphosphate — produced primarily in mitochondria. Mitochondrial dysfunction, whether from aging, inflammation, oxidative stress, or accumulated cellular damage, is increasingly recognized as a convergent mechanism in many forms of fatigue. This is where some of the most mechanistically compelling research is happening, with compounds that interact directly with mitochondrial biology.

SS-31, also known as elamipretide or Bendavia, is a cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane and stabilizes cardiolipin — a phospholipid essential for the electron transport chain and ATP production. Animal research has shown effects on mitochondrial efficiency across multiple tissues, and human clinical trials have explored it in contexts of heart failure, Barth syndrome, and age-related mitochondrial decline. Elamipretide has received FDA Breakthrough Therapy designation for Barth syndrome and has been studied in Phase II trials for primary mitochondrial myopathy. It is one of the few peptides discussed in longevity and energy contexts that has a developing human clinical trial record, though it is not FDA-approved for general use.

Humanin and MOTS-c are mitochondria-derived peptides — a category of peptides encoded within the mitochondrial genome itself, which was not widely appreciated until relatively recently. Humanin was the first identified, discovered through its ability to protect neurons from Alzheimer's-related cell death; MOTS-c was identified later for its roles in metabolic regulation and insulin sensitivity. Both have been studied in animal models for their effects on metabolism, stress resilience, and age-related decline in cellular function. MOTS-c in particular has shown interesting effects on mitochondrial biogenesis and physical performance in rodent studies. These are early-stage research compounds in the human context — the biology is genuinely interesting, the human evidence is minimal, and the appropriate framing is that they represent a direction in mitochondrial medicine that is being actively explored rather than a validated intervention.

NAD+ — nicotinamide adenine dinucleotide — is a cofactor rather than a peptide, but it belongs in this landscape because it is so deeply embedded in both mitochondrial function and cellular energy production, and because it has become one of the most-discussed interventional targets in this space. NAD+ levels decline with age. NAD+ is essential for the sirtuins — the deacetylase enzymes involved in DNA repair, stress response, and metabolic regulation — and for PARP enzymes involved in DNA damage response. Intravenous NAD+ infusions and oral precursors (NMN, NR) have been studied for fatigue, cognitive performance, and metabolic health. The clinical evidence for NAD+ supplementation for fatigue specifically is growing but not definitive; some human trials show subjective and objective improvements in energy markers, and some do not. The biological rationale is among the strongest in this category. IV NAD+ specifically has a distinct pharmacokinetic profile from oral precursors — the infusion route bypasses first-pass conversion and produces rapid plasma NAD+ elevation — though whether this translates to meaningfully different clinical outcomes remains under investigation.

AICAR — 5-aminoimidazole-4-carboxamide ribonucleotide — is an AMPK activator that mimics the cellular signals of exercise and energy depletion. AMPK is a master metabolic sensor that, when activated, promotes mitochondrial biogenesis, fatty acid oxidation, and cellular energy efficiency. Animal research on AICAR has shown dramatic effects on endurance capacity — in one widely-cited study, mice given AICAR without exercise showed improved endurance performance, which led to its informal description in some circles as "exercise in a bottle." This is not what the evidence says in humans. AICAR is a research compound, not an approved therapy, and it carries real safety considerations including effects on cell proliferation and metabolism that are not fully characterized in human long-term use.

The HPA axis — hypothalamic-pituitary-adrenal axis — is the second major mechanistic thread in fatigue peptide research. Cortisol dysregulation, whether manifesting as elevated evening cortisol that prevents sleep and recovery, or as blunted morning cortisol that fails to provide the alerting signal the brain needs to function, is a common finding in people with persistent fatigue. This is not "adrenal fatigue" in the unvalidated popular sense, but it is real HPA axis dysfunction with measurable patterns.

Selank, the synthetic anxiolytic heptapeptide discussed in the sleep context, reappears here because its effects on the GABAergic system and on enkephalin regulation have downstream implications for cortisol tone and the perceived experience of mental fatigue. In people whose fatigue is substantially driven by chronic anxiety and HPA axis overactivation — a very common pattern — compounds that reduce that overactivation without causing sedation may help restore function. Selank is not sedating in the way that benzodiazepines are; it appears to modulate anxiety without blunting cognitive function. The evidence is primarily from Russian research contexts and is not to FDA-trial standards, but the compound has a documented effect profile.

DSIP, the delta sleep-inducing peptide mentioned in the sleep overview, also has properties relevant to cortisol rhythm. Some research has suggested that DSIP may help normalize elevated cortisol in the context of chronic stress and disturbed sleep, and that its effects on sleep architecture and HPA axis modulation are related. The evidence here is genuinely preliminary.

The GH-IGF-1 axis connects to fatigue through a different mechanism. Growth hormone deficiency in adults — even subclinical, age-related decline rather than frank deficiency — is associated with reduced lean mass, impaired physical capacity, poor sleep quality, and low energy. Restoring GH axis signaling through GHRH analogues like sermorelin or GHRP combinations like ipamorelin does not stimulate energy through a direct mechanism the way a stimulant drug would; rather, it improves the conditions — sleep architecture, body composition, tissue repair — that energy depends on. People who report improved energy on sermorelin or CJC/ipamorelin protocols are likely experiencing the downstream consequences of restored slow-wave sleep and improved tissue recovery, not a direct energy-boosting effect. This is an important distinction because it sets expectations correctly: these compounds, if they help with fatigue, help slowly and indirectly, through restoring physiological conditions rather than stimulating the nervous system.

MK-677, the oral ghrelin mimetic, intersects with both sleep architecture and GH axis restoration and has been studied in contexts of body composition and metabolic function. Its relevance to fatigue is similar to that of sermorelin and ipamorelin — systemic and indirect.

Wakefulness and arousal systems are the third thread, and this is where orexin research becomes relevant again. Intranasal orexin-A has been studied in sleep-deprived primates and, in limited human contexts, as a wakefulness-promoting agent. Orexin-A's role in the narcolepsy literature is well-established; its potential as an intervention for fatigue in people without narcolepsy but with orexin-related hypersomnia or post-viral fatigue syndrome is being explored. This is research-stage work, not a clinical intervention, but it represents a direction in fatigue research that maps onto a real biological system.

Semax is a synthetic heptapeptide derived from ACTH, developed in Russia and used there as a nootropic and neuroprotective agent. It appears to increase BDNF — brain-derived neurotrophic factor — and to influence dopaminergic, serotonergic, and cholinergic systems. In the context of mental fatigue specifically — the cognitive heaviness, slow processing, and difficulty concentrating that often accompanies physical fatigue — compounds that support central neurotrophic function and neurotransmitter availability are of interest. Semax has been studied in stroke and cognitive impairment contexts in Russian clinical literature. It is not FDA-approved in the United States.

The immune-inflammatory contribution to fatigue deserves its own recognition. Chronic low-grade inflammation — now measurable through markers like high-sensitivity CRP, IL-6, and TNF-alpha — produces fatigue through mechanisms that include direct effects of inflammatory cytokines on the brain's signaling, effects on serotonin metabolism, and mitochondrial impairment in immune-active tissues. This is the biological basis of the sickness behavior that makes you want to lie down when you have an infection, and it operates at lower levels in people with chronic inflammatory conditions, post-viral states, and metabolic dysfunction. Thymosin alpha-1, an immune-modulatory peptide that has been studied in chronic fatigue contexts partly through its effects on T-cell function and inflammatory balance, appears in this landscape. BPC-157, which has anti-inflammatory properties through prostaglandin and nitric oxide pathways, is sometimes considered in this context as well. Glutathione, the endogenous antioxidant that is frequently depleted in states of chronic oxidative stress and illness, is another compound discussed in this broader framework, though technically a tripeptide rather than a functional peptide in the signaling sense.

The honest conclusion of surveying this landscape is that peptide approaches to fatigue work best — to whatever extent they work at all — when the upstream cause has been identified. Administering mitochondrial-targeted peptides when the primary driver of fatigue is untreated sleep apnea will not produce meaningful results. Pursuing GH axis restoration when the primary driver is iron deficiency anemia misses the point entirely. The complexity of the landscape is also an invitation to take the diagnostic process seriously.

Before any peptide conversation is appropriate, foundational evaluations matter: sleep architecture (not just duration but quality), thyroid function including free T3 and T4, iron studies including ferritin, sex hormone levels in the clinical context of age and symptoms, vitamin D and B12, metabolic markers including fasting glucose and insulin, and inflammatory markers. The foundational lifestyle layer — sleep, consistent physical movement, adequate dietary protein, sunlight exposure — has larger effect sizes for fatigue than any compound discussed here, and addressing it is not optional.

For someone who has done that work, who has addressed the obvious causes, and who still experiences significant fatigue that maps to a specific mechanism the research supports, the conversation with a prescribing provider who understands both the evidence and the patient's individual biology is where the legitimate clinical value of these compounds can be evaluated.